Gene · 4486
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Therapeutic Targeting of RNA Splicing in Cancer. | Genes (Basel) | 2023 | 37510283 | PubTator, text mining | PubMed |
| Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. | Cancer Res Commun | 2023 | 37476073 | PubTator, text mining | PubMed |
| Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib. | Front Pharmacol | 2023 | 37475713 | PubTator, text mining | PubMed |
| Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target. | Front Oncol | 2023 | 37469409 | PubTator, text mining | PubMed |
| GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. | Int J Mol Sci | 2023 | 37446056 | PubTator, text mining | PubMed |
| Analysis of the Mutational Landscape of Osteosarcomas Identifies Genes Related to Metastasis and Prognosis and Disrupted Biological Pathways of Immune Response and Bone Development. | Int J Mol Sci | 2023 | 37445641 | PubTator, text mining | PubMed |
| The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. | BMC Infect Dis | 2023 | 37442952 | PubTator, text mining | PubMed |
| Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment. | Ther Adv Med Oncol | 2023 | 37435563 | PubTator, text mining | PubMed |
| CARE as a wearable derived feature linking circadian amplitude to human cognitive functions. | NPJ Digit Med | 2023 | 37433859 | PubTator, text mining | PubMed |
| Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. | Acta Pharm Sin B | 2023 | 37425039 | PubTator, text mining | PubMed |
| Numerical Investigation of Transient Breakdown Voltage Enhancement in SOI LDMOS by Using a Step P-Type Doping Buried Layer. | Micromachines (Basel) | 2023 | 37421120 | PubTator, text mining | PubMed |
| Genomic characterisation of the overlap of endometriosis with 76 comorbidities identifies pleiotropic and causal mechanisms underlying disease risk. | Hum Genet | 2023 | 37410157 | PubTator, text mining | PubMed |
| The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells. | Proc Natl Acad Sci U S A | 2023 | 37399401 | PubTator, text mining | PubMed |
| Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? | Int J Mol Sci | 2023 | 37373267 | PubTator, text mining | PubMed |
| Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases. | Proteomes | 2023 | 37368466 | PubTator, text mining | PubMed |
| Preconditioned Chorionic Villus Mesenchymal Stem/Stromal Cells (CVMSCs) Minimize the Invasive Phenotypes of Breast Cancer Cell Line MDA231 In Vitro. | Int J Mol Sci | 2023 | 37298519 | PubTator, text mining | PubMed |
| The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications. | Cancers (Basel) | 2023 | 37296959 | PubTator, text mining | PubMed |
| Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer. | World J Surg Oncol | 2023 | 37287033 | PubTator, text mining | PubMed |
| Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer. | Epigenetics | 2023 | 37279148 | PubTator, text mining | PubMed |
| The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. | Front Oncol | 2023 | 37265795 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4486/papers?page=7